Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 850 | 82 | 741 |
| Samples | 276 | 27 | 246 |
| Peptides | 218 | 27 | 189 |
Function
QARS · Bifunctional glutamate/proline--tRNA ligase
Multifunctional protein which primarily functions within the aminoacyl-tRNA synthetase multienzyme complex, also known as multisynthetase complex. Within the complex it catalyzes the attachment of both L-glutamate and L-proline to their cognate tRNAs in a two-step reaction where the amino acid is first activated by ATP to form a covalent intermediate with AMP. Subsequently, the activated amino acid is transferred to the acceptor end of the cognate tRNA to form L-glutamyl-tRNA(Glu) and L-prolyl-tRNA(Pro) (PubMed:23263184, PubMed:24100331, PubMed:29576217, PubMed:3290852, PubMed:37212275). Upon interferon-gamma stimulation, EPRS1 undergoes phosphorylation, causing its dissociation from the aminoacyl-tRNA synthetase multienzyme complex. It is recruited to form the GAIT complex, which binds to stem loop-containing GAIT elements found in the 3'-UTR of various inflammatory mRNAs, such as ceruloplasmin. The GAIT complex inhibits the translation of these mRNAs, allowing interferon-gamma to redirect the function of EPRS1 from protein synthesis to translation inhibition in specific cell contexts (PubMed:15479637, PubMed:23071094). Furthermore, it can function as a downstream effector in the mTORC1 signaling pathway, by promoting the translocation of SLC27A1 from the cytoplasm to the plasma membrane where it mediates the uptake of long-chain fatty acid by adipocytes. Thereby, EPRS1 also plays a role in fat metabolism and more indirectly influences lifespan (PubMed:28178239)
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 212 amino-acid changes on canonical ENST00000306125 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in QARS · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in QARS – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Other Solid Cancers | 0/94 0% | 41/1515 3% |
| Endometrial Carcinoma | 1/42 2% | 13/612 2% |
| Melanoma | 1/210 0% | 34/1899 2% |
| Gastric Carcinoma | 2/74 3% | 19/1809 1% |
| Colorectal Carcinoma | 3/143 2% | 29/3239 1% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 12/1390 1% |
| Burkitts Lymphoma | 1/32 3% | 1/196 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 6/810 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Bladder Carcinoma | 0/58 0% | 7/956 1% |
| Ovarian Carcinoma | 1/109 1% | 6/998 1% |
| Glioma | 0/52 0% | 13/2127 1% |
| Non-Cancerous | 0/104 0% | 5/830 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Medulloblastoma | 0/0 0% | 2/450 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Neuroendocrine Tumour | 1/154 1% | 2/577 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Prostate Carcinoma | 2/13 15% | 6/2105 0% |
| Breast Carcinoma | 0/144 0% | 13/3264 0% |
| Head and Neck Carcinoma | 1/85 1% | 5/1574 0% |
| Biliary Tract Carcinoma | 0/54 0% | 3/950 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Kidney Carcinoma | 0/85 0% | 5/1862 0% |
| Hepatocellular Carcinoma | 0/46 0% | 5/2210 0% |
| Neuroblastoma | 3/87 3% | 0/1331 0% |
| B-Cell Non-Hodgkins Lymphoma | 1/88 1% | 4/2534 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 3/1592 0% |
Mutation Distribution
Where QARS is mutated · all tissues, split by cell line vs tissue
How many mutations in QARS were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 850 mutations in QARS
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|